Vitamin D, OPG/RANKL, and Inflammation with Alendronate Treatment in HIV-infected Patients with Reduced Bone Mineral Density

OBJECTIVES: To determine the effect of alendronate (ALN) on inflammatory markers and osteoprotegerin (OPG)/receptor activator of nuclear factor-kappaB ligand (RANKL), and to explore the associations of baseline systemic inflammation and vitamin D status on the bone mineral density (BMD) response to...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:HIV Med
Prif Awduron: Natsag, Javzandulam, Kendall, Michelle A., Sellmeyer, Deborah, McComsey, Grace A., Brown, Todd T.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4715784/
https://ncbi.nlm.nih.gov/pubmed/26177791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hiv.12291
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg